FDA Approves Odefsey (emtricitabine, rilpivirine and tenofovir alafenamide) for the Treatment of HIV-1 Infection

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mar. 1, 2016-- Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Odefsey (emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg or...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news